Innovation
Ubicació i contacte
Agenda
Collaborate

Oncology, Translational, Epidemiological and Clinical Research Group (GIOTEC)

CLINICAL GROUPS
ONCOLOGIA BIOINFORMÀTICA OTORINOLARINGOLOGIA ANESTESIOLOGIA
TARGETS

The IISPV’s Cancer Research Group aims to research the three main levels of oncological knowledge: population level, individual level, and molecular level.

RESPONSIBLE

  • Joan Lluís Borràs Balada

  • Josep Gumà Padró

  • Presentation
  • Lines
  • Team members
  • Publications
  • TRANSFER
  • Contact

At the population level, epidemiological data are studied from the Tarragona Cancer Registry and the results of population screening programs are reported.

From the individual point of view (patient-level), clinical trials are performed with new drugs or new combinations of the same in most tumor locations.

At the basic or molecular level, the Unit focuses on mutations in hereditary cancer, somatic tumor mutations, the relationship between lipids and cancer, and metabolomic studies in different tumors from both a diagnostic and prognostic point of view.

Clinical research

a. Clinical trials in phases II and III, and Real-World Studies of the main tumor locations.
b. Basket Trial-type clinical trials for tumors with certain genetic mutations.
c. Studies of prognostic and predictive response factors.

Epidemiological research

Responsible: Dr. Jaume Galceran
a. In the field of epidemiological research, it focuses on population-based studies related to the Tarragona Cancer Registry.
b. In the field of prevention research focuses on studies related to cancer screening.

Basic and translational research

a. Hereditary breast and ovarian cancer: a study of mutations of uncertain significance in BRCA genes, application of Next Generation Sequencing in the identification of new pathogenic mutations, and metabolomics of hereditary breast cancer cell lines.
Responsible: Dra. Marta Rodríguez

b. Precision oncology. Somatic study. Study of tumor mutations, including liquid biopsy, for clinical and research application, the basis of new therapeutic targets. Joint collaboration between the Pathological Anatomy Service, Medical Oncology and the Genetic Counseling Unit.
Responsible: Dr. Francesc Riu

c.  Lipid metabolism and cancer: the role of fatty acid transporter proteins in tumor progression (Collaboration with the IISPV Lipid Unit).
Responsible: Dr. Josep Gumà / Dra. Sandra Guaita 

d.  Metabolomics: Metabolic profile in biological fluids for early diagnosis of colorectal cancer, as a predictor of response to immunotherapy in lung cancer, and as a prognostic factor in aggressive lymphomas.
Responsible: Dr. Josep Gumà

Research in psychooncology
Responsible: Dra. Agustina Sirgo

a. Study the impact of oncological disease. At the social level, the study of the benefits of the self-help group of women with breast cancer.

    Year

    Incidence and Clinical Pattern of Contralateral Synchronous and Metachronous Germ Cell Testicular Cancer

    Maroto P, García Del Muro X, Valverde C, Pinto A, Sanchez A, Guma J, Alonso T, Martínez Del Prado P, Vazquez S, Mellado B, Aparicio J, Fernandez-Aramburo A, Girones R, Terrasa J; Spanish Germ Cell Cancer Group.Urol Oncol. 2020 Nov 11:S1078-1439(20)30573-1. doi: 10.1016/j.urolonc.2020.11.004. Epub ahead of print. PMID: 33189529.

    Liquid-based cytological and immunohistochemical study of nasopharyngeal swab from persons under investigation for SARS-CoV-2 infection

    Parada D D, Peña KB, Gumá J, Guilarte C, Riu F.  Histopathology. 2020 Sep 24:10.1111/his.14257. doi: 10.1111/his.14257. Epub ahead of print. PMID: 32970870; PMCID: PMC7537171.

    Population-based risk assessment of second primary cancers following a first head and neck cancer: patterns of association and difficulties of its analysis.

    Rubió-Casadevall J, Galceran J, Ameijide A, Puigdemont M, Llauradó L, Marruecos J, Izquierdo A, Carulla M, Borràs JL, Marcos-Gragera R, Gumà J.Clin Transl Oncol. 2020 Aug 19. doi: 10.1007/s12094-020-02470-z. Epub ahead of print. PMID: 32815088.

    Proactive and systematic multidimensional needs assessment in patients with advanced cancer approaching palliative care: a study protocol

    Pergolizzi D, Crespo I, Balaguer A, Monforte-Royo C, Alonso-Babarro A, Arantzamendi M, Belar A, Centeno C, Goni-Fuste B, Julià-Torras J, Martinez M, Mateo-Ortega D, May L, Moreno-Alonso D, Nabal Vicuña M, Noguera A, Pascual A, Perez-Bret E, Rocafort J, Rodríguez-Prat A, Rodriguez D, Sala C, Serna J, Porta-Sales J. BMJ Open. 2020 Feb 4;10(2):e034413. doi: 10.1136/bmjopen-2019-034413. PMID: 32024792; PMCID: PMC7045209

    A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond six cycles in patients with glioblastoma (GEINO 14-01)

    Balana C, Vaz MA, Sepúlveda JM, Mesia C, Del Barco S, Pineda E, Muñoz-Langa J, Estival A, de Las Peñas R, Fuster J, Gironés R, Navarro LM, Gil-Gil M, Alonso M, Herrero A, Peralta S, Olier C, Perez-Segura P, Covela M, Martinez-García M, Berrocal A, Gallego O, Luque R, Perez-Martín FJ, Esteve A, Munne N, Domenech M, Villa S, Sanz C, Carrato C. Neuro Oncol. 2020 Apr 24:noaa107. doi: 10.1093/neuonc/noaa107. Epub ahead of print. PMID: 32328662.

    Palbociclib and Trastuzumab in HER2-Positive Advanced Breast Cancer: Results from the Phase II SOLTI-1303 PATRICIA Trial

    Ciruelos E, Villagrasa P, Pascual T, Oliveira M, Pernas S, Paré L, Escrivá-de-Romaní S, Manso L, Adamo B, Martínez E, Cortés J, Vazquez S, Perelló A, Garau I, Melé M, Martínez N, Montaño A, Bermejo B, Morales S, Echarri MJ, Vega E, González-Farré B, Martínez D, Galván P, Canes J, Nuciforo P, Gonzalez X, Prat A. Clin Cancer Res. 2020 Nov 15;26(22):5820-5829. doi: 10.1158/1078-0432.CCR-20-0844. Epub 2020 Sep 16. PMID: 32938620.

    Quality of life of patients with metastatic pancreatic adenocarcinoma initiating first-line chemotherapy in routine practice.

    Laquente B, Macarulla T, Bugés C, Martín M, García C, Pericay C, Merino S, Visa L, Martín T, Pedraza M, Carnero B, Guardeño R, Verdaguer H, Mut A, Vilanova D, García A. BMC Palliat Care. 2020 Jul 10;19(1):103. doi: 10.1186/s12904-020-00610-4. PMID: 32650765; PMCID: PMC7350578.

    Circulating microRNAs modulating glycolysis as non-invasive prognostic biomarkers of HNSCC.

    Avilés-Jurado FX, Muñoz C, Meler C, Flores JC, Gumà J, Benaiges E, Mora J, Camacho M, León X, Vilaseca I, Terra X. Eur Arch Otorhinolaryngol. 2020 Jul 31. doi: 10.1007/s00405-020-06240-z. Epub ahead of print. PMID: 32737645.

    Patterns of relapse and treatment outcome after active surveillance or adjuvant carboplatin for stage I seminoma: a retrospective study of the Spanish Germ Cell Cancer Group

    Aparicio J, García Del Muro X, Maroto P, Terrasa J, Castellano D, Bastús R, Gumà J, Sagastibeltza N, Durán I, Ochenduszko S, Meana JA, García-Sánchez J, Arranz JA, Gironés R, Germà JR. Clin Transl Oncol. 2020 May 27. doi: 10.1007/s12094-020-02393-9. Epub ahead of print. PMID: 32462393.

    Missing data imputation and synthetic data simulation through modeling graphical probabilistic dependencies between variables (ModGraProDep): An application to breast cancer survival

    Vilardell M, Buxo M, Cleries R, Martinez JM, Garcia G, Ameijide A, Font R, Civit S, Marcos-Gragera R, Vilardell ML, Carulla M, Espinas JA, Galceran J, Izquierdo A, Borras JM.
    Artif Intell Med. 2020 Jul;107:101875.
    DOI: 10.1016/j.artmed.2020.101875

     

    Differences in breast cancer risk after benign breast disease by type of screening diagnosis.

    Louro J, Roman M, Posso M, Comerma L, Vidal C, Saladie F, Alcantara R, Sanchez M, Quintana MJ, del Riego J, Ferrer J, Penalva L, Bargallo X, Prieto M, Sala M, Castells X.
    Breast. 2020 Dec;54:343-348.
    DOI: 10.1016/j.breast.2020.09.005

     

    Rare thyroid malignancies in Europe: Data from the informationnetwork on rare cancers in Europe (RARECAREnet).

    Locati L, Cavalieri S, Dal Maso L, Busco S, Anderson L, Botta L, Bento MJ, Carulla M, Chirlaque López MD, Fusco M, Guevara M, Innos K, BørgeJohannesen T, Micallef R, Minicozzi P, Panato C, Petrova D, Rubio Casadevall J, Smailyte G, Vitale MF, Trama A.
    Oral Oncol. 2020 Sep;108:104766.
    DOI: 10.1016/j.oraloncology.2020.104766 

    A population perspective on the use of external beam radiotherapy in Catalonia, Spain.

    Corral J, Solà J, Galceran J, Marcos-Gragera R, Carulla M, Izquierdo Á, Vilardell L, Llauradó L, Espinàs J, Borras JM.
    Clin Transl Oncol. 2020 Dec;22(12):2222-2229.
    DOI: 10.1007/s12094-020-02355-1

     

    Long-term follow-up of patients with nodular lymphocyte predominant Hodgkin lymphoma: A report from the Spanish Lymphoma Oncology Group.

    Núñez-García B, Rodríguez-Pertierra M, Sequero S, Carvajal LG, Ruano-Ravina A, Aguiar D, Gumá J, Blanco CQ, García Arroyo FR, Garitaonaindia Y, Provencio Z, Calvo V, González-San Segundo C, Provencio M.
    First published: Hematol Oncol. 2020 Dec
    DOI: 10.1002/hon.2835

     

    Excess mortality among breast cancer patients in early stages in Tarragona and Gerona

    Clèries R, Ameijide A, Buxó M, Vilardell M, Martínez JM, Marcos-Gragera R, Vilardell ML, Carulla M, Espinàs JA, Galceran J, Borràs JM, Izquierdo Á.
    Gac Sanit. Jul-Aug 2020;34(4):356-362.
    DOI: 10.1016/j.gaceta.2018.09.008.

     

    Protocolo del Estudio Poblacional Multinivel de las Desigualdades Socioeconómicas en la Distribución Geográfica de la Incidencia, la Mortalidad y la Supervivencia Neta del Cáncer en España: Estudio DESOCANES.

    Luque-Fernández MA, Redondo-Sánchez D, Fernández P, Salamanca-Fernández E, Marcos-Gragera R, Guevara M, Carulla M, Jiménez R, Núñez O, Sabater C, López de Munain A, Chirlaque MD, Mateos A, Rodríguez-Barranco M, Espín J, Pollán M, Sánchez MJ.
    2020 JuL 13 [Epub ahead of print]. Gac Sanit.
    DOI: 10.1016/j.gaceta.2020.02.015

     

    Identification of germline pathogenic variants in DNA damage repair genes by a next-generation sequencing multigene panel in BRCAX patients

    Rodríguez-Balada M, Roig B, Melé M, Albacar C, Serrano S, Salvat M, Querol M, Borràs J, Martorell L, Gumà J. Clin Biochem. 2020 Feb;76:17-23. doi: 10.1016/j.clinbiochem.2019.11.014. Epub 2019 Nov 28. PMID: 31786208.

    Neoadjuvant Metformin Added to Systemic Therapy Decreases the Proliferative Capacity of Residual Breast Cancer

    Lopez-Bonet E, Buxó M, Cuyàs E, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Oliveras G, Meléndez C, Castillo L, Verdura S, Brunet J, Joven J, Garcia M, Saidani S, Martin-Castillo B, Menendez JA. J Clin Med. 2019 Dec 11;8(12):2180. doi: 10.3390/jcm8122180. PMID: 31835708; PMCID: PMC6947627.

    Metformin induces a fasting- and antifolate-mimicking modification of systemic host metabolism in breast cancer patients

    Cuyàs E, Fernández-Arroyo S, Buxó M, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Verdura S, Brunet J, López-Bonet E, Garcia M, Saidani S, Joven J, Martin-Castillo B, Menendez JA. Aging (Albany NY). 2019 May 9;11(9):2874-2888. doi: 10.18632/aging.101960. PMID: 31076561; PMCID: PMC6535060.

    The C Allele of ATM rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin.

    Cuyàs E, Buxó M, Ferri Iglesias MJ, Verdura S, Pernas S, Dorca J, Álvarez I, Martínez S, Pérez-Garcia JM, Batista-López N, Rodríguez-Sánchez CA, Amillano K, Domínguez S, Luque M, Morilla I, Stradella A, Viñas G, Cortés J, Joven J, Brunet J, López-Bonet E, Garcia M, Saidani S, Queralt Moles X, Martin-Castillo B, Menendez JA. Front Oncol. 2019 Mar 28;9:193. doi: 10.3389/fonc.2019.00193. PMID: 30984619; PMCID: PMC6447648.

    Effects of radiotherapy on plasma energy metabolites in patients with breast cancer who received neoadjuvant chemotherapy

    Arenas M, Fernández-Arroyo S, Rodríguez-Tomàs E, Sabater S, Murria Y, Gascón M, Amillano K, Melé M, Camps J, Joven J. Clin Transl Oncol. 2020 Jul;22(7):1078-1085. doi: 10.1007/s12094-019-02232-6. Epub 2019 Nov 2. PMID: 31679126.

    Treatment and Outcome of Patients with Stage IS Testicular Cancer: A Retrospective Study from the Spanish Germ Cell Cancer Group

    Aparicio J, Sánchez-Muñoz A, Ochenduszko S, Gumà J, Fernández-Aramburo A, García Del Muro X, Quiroga V, Sastre J, Alonso-Gordoa T, Sagastibelza N, Maroto P, Gómez de Liaño A, Vázquez S, Diz P, Durán I, Domenech M, Pinto A, Hernández A, González-Billalabeitia E, Terrasa J. J Urol. 2019 Oct;202(4):742-747. doi: 10.1097/JU.0000000000000366. Epub 2019 Sep 6. PMID: 31163007.

    Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

    Méndez M, Torrente M, Sánchez-Beato M, González-Rincón J, Royuela A, Gómez-Codina J, de la Cruz-Merino L, Rueda A, Llanos M, Quero C, Rodríguez-Abreu D, Gumá J, Monsalvo S, Sabin P, Provencio M. Hematol Oncol. 2019 Apr;37(2):143-150. doi: 10.1002/hon.2601. Epub 2019 Apr 4. PMID: 30840776.

    Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

    Provencio M, Franco F, Gómez-Codina J, Quero Blanco C, Llanos M, Garcia-Arroyo F, de la Cruz L, Gumá J, Delgado JR, Álvarez R, Chacón JI, Royuela A, Rueda A. Leuk Lymphoma. 2019 Mar;60(3):856-859. doi: 10.1080/10428194.2018.1509322. Epub 2018 Sep 20. PMID: 30234403.

    Guies de pràctica clínica

  • Aparicio J, Terrasa J, Durán I, Germà-Lluch JR, Gironés R, González-Billalabeitia E, Gumà J, Maroto P, Pinto A, García-Del-Muro X. SEOM clinical guidelines for the management of germ cell testicular cancer (2016). Clin Transl Oncol. 2016 Dec;18(12):1187-1196. doi: 10.1007/s12094-016-1566-1. Epub 2016 Nov 4. PMID: 27815687; PMCID: PMC5138244.

  • Rueda Domínguez A, Alfaro Lizaso J, de la Cruz Merino L, Gumá i Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Provencio Pulla M. SEOM clinical guidelines for the treatment of Hodgkin’s lymphoma. Clin Transl Oncol. 2015 Dec;17(12):1005-13. doi: 10.1007/s12094-015-1429-1. Epub 2015 Oct 26. PMID: 26497354; PMCID: PMC4689754.

     

  • Provencio Pulla M, Alfaro Lizaso J, de la Cruz Merino L, Gumá i Padró J, Quero Blanco C, Gómez Codina J, Llanos Muñoz M, Martinez Banaclocha N, Rodriguez Abreu D, Rueda Domínguez A. SEOM clinical guidelines for the treatment of follicular non-Hodgkin’s lymphoma. Clin Transl Oncol. 2015 Dec;17(12):1014-9. doi: 10.1007/s12094-015-1437-1. Epub 2015 Nov 19. PMID: 26586117; PMCID: PMC4689757.

  • Aldea A, Arriola E, Borràs JM, Bosch J, Carreras MJ, Conde D, Córdoba JF, Felip E, Fontanals S, Guarga L, Majem M, Mangues I, Martínez J, Moreno E, Nadal E, Peralta S, Rodríguez MC, Serrano G, Vilà L, Viñolas N. Programa d’harmonització farmacoterapèutica. Pautes per a l’harmonització del tractament farmacològic del càncer de pulmó no microcític metastàtic. Gasol M, Gay D, Guarga L, Martínez J, Puig G, Sancho A, Solós G coord. Pontes C, Ballano A Direcció. Barcelona: Servei Català de la Salut. Departament de Salut. Generalitat de Catalunya; 2021.

Team Members

  • Group leader

    • Joan Lluís Borràs Balada

  • Responsable de grup

    • Josep Gumà Padró

  • Group leader

    • Agustina Sirgo Rodríguez
    • Marta Rodríguez Balada
    • Francesc Riu Ferrando
    • Sandra Guaita Esteruelas
    • Jaume Galceran Padrós

  • PhD

    • Bàrbara Roig Bourgine
    • Karla Peña González
    • David Parada Domíngues
    • Xavier Cardó Moreno

  • Pre-Doctoral Researcher

    • Clara Beatriz Lucia Gozálvez
    • José Adrià Cebrián

  • MD

    • Sara Serrano Solares
    • Belen Ruiz Aguado
    • Beatriz Rubio Cantavella
    • Dulce Rodríguez Mesa
    • Jana Repkovà
    • Rosana Queralt Escarré
    • Sergio Peralta Muño
    • Félix Muñoz Boza
    • Vanesa Morente Laguna
    • Maria José Miranda Pallares
    • Sandra Merino Varela
    • Mireia Melé Olivé
    • Maria Masvidal Hernández
    • Francisca Martínez Madueño
    • Cristina Martí Blanco
    • Inés Cabezas Montero
    • David Ricardo Bottaro Parra
    • Kepa Amillano Parraga
    • Cinta Albacar Miró

  • Senior researcher

    • Cristina Miracle Huguet
    • Marta Vilaró Pacheco
    • Francina Saladié Roiget
    • Clàudia Pla González
    • Sara Fernández Castillejo
    • Xavier Collado Castro
    • Marià Carulla Areste
    • Jàmnica Bigorra Román
    • Alberto Ameijide Sánchez

  • DUI

    • Montse Sánchez Galino
    • Mònica Salvat Casas
    • M. Dolors Salsench Boronat
    • Montserrat Querol Garcia
    • Margarita Moreno Mancho
    • Sandra Mateu Riba
    • Araceli Jiménez López
    • Francesca Isern Català
    • Immaculada Grau Farrús
    • Berta Caballé Gutiérrez

  • Technician

    • Laia Llauradó March
    • Lydia Díaz Suárez
    • Alexandra Cabré Pedrosa
    • Anna Alimbau Sendrós

Altres grups de Clinical Groups

See all